VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Verrica Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.44−0.16 (-4.31%)
Close on Oct 19, 2026
- Market cap
- $73.29M
- P/E (TTM)
- –
- Dividend yield
- –
Verrica Pharmaceuticals Inc. cash flow statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -93.6%
- Net margin
- -102.8%
- Return on equity, FY2025
- -240.4%
Financial strength
- Current ratio
- 1.45
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 49.9%
Valuation
- P/E ratio
- –
- Price to sales
- 2.42
- Price to book
- 17.02
- Dividend yield
- –